

Kirsten Sundby Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3413852/publications.pdf>

Version: 2024-02-01

58
papers

3,052
citations

201674

27
h-index

161849

54
g-index

58
all docs

58
docs citations

58
times ranked

3614
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrinogen-like protein 2 in gastrointestinal stromal tumour. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1083-1094.	3.6	3
2	Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study. <i>Acta Oncologica</i> , 2022, 61, 793-800.	1.8	1
3	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2617-2624.	4.2	45
4	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
5	Striving towards Normality in Daily Life: A Qualitative Study of Patients Living with Metastatic Gastrointestinal Stromal Tumour in Long-Term Clinical Remission. <i>Sarcoma</i> , 2020, 2020, 1-9.	1.3	7
6	Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study. <i>Clinical Sarcoma Research</i> , 2020, 10, 22.	2.3	3
7	The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review. <i>Frontiers in Oncology</i> , 2020, 10, 1402.	2.8	7
8	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2020, 6, 1241.	7.1	111
9	Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11502-11502.	1.6	34
10	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019, 109, 36-50.	2.8	354
11	Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas – A nationwide population-based study. <i>Journal of Bone Oncology</i> , 2019, 14, 100207.	2.4	10
12	Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11007-11007.	1.6	20
13	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	7.1	63
14	Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 1133-1139.	1.5	40
15	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , 2018, 104, 30-36.	1.1	84
16	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	3.7	62
17	Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway. <i>Journal of Surgical Oncology</i> , 2018, 118, 246-247.	1.7	2
18	Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. <i>Modern Pathology</i> , 2018, 31, 1694-1707.	5.5	11

#	ARTICLE	IF	CITATIONS
19	Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factorsâ€”A Scandinavian Sarcoma Groupâ€”study (SSG XX). <i>European Journal of Cancer</i> , 2018, 99, 78-85.	2.8	26
20	Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. <i>PLoS ONE</i> , 2018, 13, e0193048.	2.5	17
21	Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort. <i>Acta OncolÃ³gica</i> , 2017, 56, 479-483.	1.8	23
22	The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2017, 88, 341-347.	3.3	38
23	Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. <i>Acta OncolÃ³gica</i> , 2017, 56, 1317-1323.	1.8	15
24	Effect of <i>KIT</i> and <i>PDGFRA</i> Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib. <i>JAMA Oncology</i> , 2017, 3, 602.	7.1	141
25	SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour. <i>British Journal of Cancer</i> , 2017, 116, 1195-1202.	6.4	13
26	Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35Åyears. <i>Neurosurgical Review</i> , 2017, 40, 449-460.	2.4	16
27	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in <i>PDGFRA</i> : The CrenoGIST study.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11080-TPS11080.	1.6	11
28	Failure rate of standard rescue with leucovorin for high-dose methotrexate (HDMTX) in osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11028-11028.	1.6	0
29	Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour â€” Does it increase the risk for tumour cell seeding and recurrence?. <i>European Journal of Cancer</i> , 2016, 59, 128-133.	2.8	39
30	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1396-1408.	10.7	356
31	Metastatic mesenteric dedifferentiated leiomyosarcoma: a case report and a review of literature. <i>Clinical Sarcoma Research</i> , 2016, 6, 2.	2.3	12
32	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 244-250.	1.6	174
33	Referral patterns, treatment and outcome of highâ€”grade malignant bone sarcoma in Scandinaviaâ€”SSG Central Register 25 years' experience. <i>Journal of Surgical Oncology</i> , 2015, 112, 853-860.	1.7	13
34	Prognostic Factors and Treatment Results of High-Grade Osteosarcoma in Norway: A Scope Beyond the â€”Classicalâ€”Patient. <i>Sarcoma</i> , 2015, 2015, 1-14.	1.3	36
35	Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. <i>Neuro-Oncology</i> , 2015, 17, 63-69.	1.2	17
36	Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2279-2287.	1.6	329

#	ARTICLE	IF	CITATIONS
37	Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours – A prognostic test after surgical resection. <i>Molecular Oncology</i> , 2015, 9, 1129-1139.	4.6	32
38	Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1. <i>Journal of Clinical Oncology</i> , 2015, 33, 10512-10512.	1.6	4
39	High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 840-845.	1.5	39
40	MAP plus maintenance pegylated interferon β -2b (MAP-IFN) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 – good response – randomization. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10504-LBA10504.	1.6	14
41	MAP plus maintenance pegylated interferon β -2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA10504-LBA10504.	1.6	4
42	High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 106-114.	2.4	101
43	EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 10081-10081.	1.6	3
44	Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2011, 82, 211-216.	3.3	53
45	Five-Year Results From a Scandinavian Sarcoma Group Study (SSG XIII) of Adjuvant Chemotherapy Combined With Accelerated Radiotherapy in High-Risk Soft Tissue Sarcoma of Extremities and Trunk Wall. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1359-1366.	0.8	20
46	DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour. <i>Acta Oncologica</i> , 2011, 50, 148-150.	1.8	15
47	The Scandinavian Sarcoma Group. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2009, 80, 1-104.	3.3	16
48	Small Round Cell Sarcomas. <i>Seminars in Oncology</i> , 2009, 36, 338-346.	2.2	28
49	Radiotherapy to Improve Local Control Regardless of Surgical Margin and Malignancy Grade in Extremity and Trunk Wall Soft Tissue Sarcoma: A Scandinavian Sarcoma Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1196-1203.	0.8	129
50	Radiation-induced sarcoma: 25-year experience from The Norwegian Radium Hospital. <i>Acta Oncologica</i> , 2008, 47, 1475-1482.	1.8	93
51	Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. <i>Cancer</i> , 2007, 109, 282-291.	4.1	123
52	Young survivors of malignant bone tumours in the extremities: a comparative study of quality of life, fatigue and mental distress. <i>Supportive Care in Cancer</i> , 2007, 15, 1087-1096.	2.2	44
53	Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience. <i>Acta Oncologica</i> , 2006, 45, 38-46.	1.8	30
54	Time dependence of prognostic factors for patients with soft tissue sarcoma. <i>Cancer</i> , 2004, 100, 2233-2239.	4.1	36

#	ARTICLE	IF	CITATIONS
55	Chemotherapy in soft tissue sarcoma. <i>Acta Orthopaedica</i> , 1999, 70, 62-68.	1.4	20
56	Verapamil Potentiates 4-epidoxorubicin Cytotoxicity in a Rat Hepatoma Cell Line and in a Substrain Resistant to 4-epidoxorubicin. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 67, 402-405.	0.0	3
57	The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4-epidoxorubicin in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 444-448.	2.3	4
58	High-dose cis-platinum combination chemotherapy in advanced nonseminomatous malignant germ cell tumours with emphasis on nephrotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 74-77.	2.3	12